The stock's fall snapped a two-day winning streak.

Corbus Pharmaceuticals Holdings Inc. closed 88.89% short of its 52-week high of $61.90, which the company reached on July 31st.

Fintel reports that on February 28, 2025, William Blair initiated coverage of Corbus Pharmaceuticals Holdings (NasdaqCM:CRBP) ...

Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report) was upgraded by equities research analysts at StockNews.com to a “sell” rating in a report released on Thursday. Several other brokerages also ...

CRB-701 Nectin-4 targeting ADC demonstrates encouraging results in Phase 1 Western study; Fast Track Designation granted by ...

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private ...

Corbus Pharmaceuticals has a twelve month low of $6.54 and a twelve month high of $61.90. The firm has a market cap of $82.70 million, a P/E ratio of -1.45 and a beta of 2.63.

Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall readout is in line with the Chinese data that drummed up excitement in the ...

NORWOOD, Mass. (AP) — NORWOOD, Mass. (AP) — Corbus Pharmaceuticals Holdings Inc. (CRBP) on Tuesday reported a loss of $9.5 million in its fourth quarter. The Norwood, Massachusetts-based company said ...

Corbus Pharmaceuticals announced results from its first-in-human dose escalation study of CRB-701, presented at the ASCO GU 2025 conference. This Phase 1 study assessed the efficacy and safety of ...

Today, we talk about that, as well as new cancer data from Corbus Pharma ... RFK Jr. sworn in as health secretary, leading MAHA Robert F. Kennedy Jr. has been sworn in as the U.S. health secretary ...